EIP
ALNY icon

Ellis Investment Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ellis Investment Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11
Closed -$1K – 784
2022
Q1 		$1K Hold
11
– – ﹤0.01% 775
2021
Q4 		$1K Buy
+11
New +$2.04K ﹤0.01% 771

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ellis Investment Partners's ALNY Position: Q2 2022 in Review

Ellis Investment Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2022, closing a stake of 11 shares — an estimated $1K sold.

Ellis Investment Partners first reported a position in ALNY in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 423 funds tracked by Wall St. Rank hold ALNY as of Q2 2022.

  • Ellis Investment Partners reported no remaining Alnylam Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Ellis Investment Partners sold 11 Alnylam Pharmaceuticals shares in Q2 2022, an estimated $1K.
  • Ellis Investment Partners first reported a position in Alnylam Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Ellis Investment Partners's Alnylam Pharmaceuticals position peaked at $1K in Q1 2022.
  • 423 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2022.

Based on Ellis Investment Partners's 13F filing for Q2 2022, filed 1 Aug 2022.